These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37603347)

  • 41. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.
    Locatelli F; Antmen B; Kang HJ; Koh K; Takahashi Y; Kupesiz A; Dias Matos MGA; Chopra Y; Bhat S; Im HJ; Güngör T; Lu MY; Stefanelli T; Rosko C; St Pierre A; Burock K; Smith Y; Sinclair K; Diaz-de-Heredia C
    Lancet Haematol; 2024 Aug; 11(8):e580-e592. PubMed ID: 39002551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
    Teusink-Cross A; Davies SM; Grimley MS; Chandra S; Flannery A; Dandoy CE; Nelson AS; Marsh RA; Jacoby B; Lane A; Khandelwal P
    Pediatr Transplant; 2020 May; 24(3):e13692. PubMed ID: 32202691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis.
    Fante MA; Holler B; Weber D; Angstwurm K; Bergler T; Holler E; Edinger M; Herr W; Wertheimer T; Wolff D
    Ann Hematol; 2020 Sep; 99(9):2181-2190. PubMed ID: 32715339
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients.
    Faraci M; Calevo MG; Giardino S; Leoni M; Ricci E; Castagnola E; Lanino E
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):743-748. PubMed ID: 30471340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Inagaki J; Fukano R; Kodama Y; Nishimura M; Shimokawa M; Okamura J
    Ann Hematol; 2014 Apr; 93(4):645-51. PubMed ID: 24146233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Waller EK; Miklos D; Cutler C; Arora M; Jagasia MH; Pusic I; Flowers MED; Logan AC; Nakamura R; Chang S; Clow F; Lal ID; Styles L; Jaglowski S
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2002-2007. PubMed ID: 31260802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
    Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
    Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
    Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
    Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
    Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
    Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
    Matsuoka K; Koreth J; Kim HT; Bascug G; McDonough S; Kawano Y; Murase K; Cutler C; Ho VT; Alyea EP; Armand P; Blazar BR; Antin JH; Soiffer RJ; Ritz J
    Sci Transl Med; 2013 Apr; 5(179):179ra43. PubMed ID: 23552371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Prospective, Multicenter Study of Closed-System Extracorporeal Photopheresis for Children with Steroid-Refractory Acute Graft-versus-Host Disease.
    Kitko CL; Abdel-Azim H; Carpenter PA; Dalle JH; Diaz-de-Heredia C; Gaspari S; Gennery AR; Handgretinger R; Lawitschka A
    Transplant Cell Ther; 2022 May; 28(5):261.e1-261.e7. PubMed ID: 35124293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.
    Ilhan O; Arat M; Arslan O; Ayyildiz E; Sanli H; Beksac M; Ozcan M; Gürman G; Akan H
    Transfus Apher Sci; 2004 Jun; 30(3):185-7. PubMed ID: 15172621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tocilizumab for steroid refractory acute graft-versus-host disease.
    Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
    Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.
    Rozmus J; Schultz KR; Wynne K; Kariminia A; Satyanarayana P; Krailo M; Grupp SA; Gilman AL; Goldman FD
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1804-13. PubMed ID: 21669298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis.
    Wertheimer T; Dohse M; Afram G; Weber D; Heidenreich M; Holler B; Kattner AS; Neubauer A; Mielke S; Ljungman P; Holler E; Herr W; Edinger M; Martínez AP; Fante M; Wolff D
    Ann Hematol; 2021 Mar; 100(3):779-787. PubMed ID: 33515310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease.
    Choi JY; Kim H; Baek HJ; Kook H; Lee JM; Kim BK; An HY; Hong KT; Shin HY; Kang HJ
    Transplant Cell Ther; 2021 Nov; 27(11):925.e1-925.e7. PubMed ID: 34314892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.